Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy
© The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America..
The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting.
TRIAL REGISTRATION: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2021 |
|---|---|
| Erschienen: |
2021 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:8 |
|---|---|
| Enthalten in: |
Open forum infectious diseases - 8(2021), 9 vom: 17. Sept., Seite ofab420 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Schultz-Cherry, Stacey [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Antibody |
|---|
| Anmerkungen: |
Date Revised 26.04.2022 published: Electronic-eCollection ClinicalTrials.gov: NCT04362995 Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.1093/ofid/ofab420 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM33099252X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM33099252X | ||
| 003 | DE-627 | ||
| 005 | 20231225212504.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1093/ofid/ofab420 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1103.xml |
| 035 | |a (DE-627)NLM33099252X | ||
| 035 | |a (NLM)34557558 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Schultz-Cherry, Stacey |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Cross-reactive Antibody Response to mRNA SARS-CoV-2 Vaccine After Recent COVID-19-Specific Monoclonal Antibody Therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 26.04.2022 | ||
| 500 | |a published: Electronic-eCollection | ||
| 500 | |a ClinicalTrials.gov: NCT04362995 | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a © The Author(s) 2021. Published by Oxford University Press on behalf of Infectious Diseases Society of America. | ||
| 520 | |a The efficacy of coronavirus disease 2019 (COVID-19) vaccines administered after COVID-19-specific monoclonal antibody is unknown, and "antibody interference" might hinder immune responses leading to vaccine failure. In an institutional review board-approved prospective study, we found that an individual who received mRNA COVID-19 vaccination <40 days after COVID-19-specific monoclonal antibody therapy for symptomatic COVID-19 had similar postvaccine antibody responses to SARS-CoV-2 receptor binding domain (RBD) for 4 important SARS-CoV-2 variants (B.1, B.1.1.7, B.1.351, and P.1) as other participants who were also vaccinated following COVID-19. Vaccination against COVID-19 shortly after COVID-19-specific monoclonal antibody can boost and expand antibody protection, questioning the need to delay vaccination in this setting | ||
| 520 | |a TRIAL REGISTRATION: The St. Jude Tracking of Viral and Host Factors Associated with COVID-19 study; NCT04362995; https://clinicaltrials.gov/ct2/show/NCT04362995 | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a COVID-19 | |
| 650 | 4 | |a SARS-CoV-2 | |
| 650 | 4 | |a antibody | |
| 650 | 4 | |a bamlanivimab | |
| 650 | 4 | |a vaccine failure | |
| 700 | 1 | |a McGargill, Maureen A |e verfasserin |4 aut | |
| 700 | 1 | |a Thomas, Paul G |e verfasserin |4 aut | |
| 700 | 1 | |a Estepp, Jeremie H |e verfasserin |4 aut | |
| 700 | 1 | |a Gaur, Aditya H |e verfasserin |4 aut | |
| 700 | 1 | |a Allen, E Kaitlynn |e verfasserin |4 aut | |
| 700 | 1 | |a Allison, Kim J |e verfasserin |4 aut | |
| 700 | 1 | |a Tang, Li |e verfasserin |4 aut | |
| 700 | 1 | |a Webby, Richard J |e verfasserin |4 aut | |
| 700 | 1 | |a Cherry, Sean D |e verfasserin |4 aut | |
| 700 | 1 | |a Lin, Chun-Yang |e verfasserin |4 aut | |
| 700 | 1 | |a Fabrizio, Thomas |e verfasserin |4 aut | |
| 700 | 1 | |a Tuomanen, Elaine I |e verfasserin |4 aut | |
| 700 | 1 | |a Wolf, Joshua |e verfasserin |4 aut | |
| 700 | 0 | |a SJTRC Investigative Team |e verfasserin |4 aut | |
| 700 | 1 | |a Kirkpatrick Roubidoux, Ericka |e investigator |4 oth | |
| 700 | 1 | |a Freiden, Pamela |e investigator |4 oth | |
| 700 | 1 | |a Mori, Tomi |e investigator |4 oth | |
| 700 | 1 | |a Hijano, Diego R |e investigator |4 oth | |
| 700 | 1 | |a Hakim, Hana |e investigator |4 oth | |
| 700 | 1 | |a Brice, David C |e investigator |4 oth | |
| 700 | 1 | |a Castellaw, Ashley |e investigator |4 oth | |
| 700 | 1 | |a Krammer, Florian |e investigator |4 oth | |
| 700 | 1 | |a Wittman, David E |e investigator |4 oth | |
| 700 | 1 | |a Hodges, Jason |e investigator |4 oth | |
| 700 | 1 | |a Dallas, Ronald H |e investigator |4 oth | |
| 700 | 1 | |a Cortez, Valerie |e investigator |4 oth | |
| 700 | 1 | |a Vazquez-Pagan, Ana |e investigator |4 oth | |
| 700 | 1 | |a Bajracharya, Resha |e investigator |4 oth | |
| 700 | 1 | |a Clark, Brandi L |e investigator |4 oth | |
| 700 | 1 | |a Van de Velde, Lee-Ann |e investigator |4 oth | |
| 700 | 1 | |a Awad, Walid |e investigator |4 oth | |
| 700 | 1 | |a Wilson, Taylor L |e investigator |4 oth | |
| 700 | 1 | |a Kirk, Allison M |e investigator |4 oth | |
| 700 | 1 | |a Hayden, Randall T |e investigator |4 oth | |
| 700 | 1 | |a Hoffman, James |e investigator |4 oth | |
| 700 | 1 | |a Russell-Bell, Jamie |e investigator |4 oth | |
| 700 | 1 | |a Sparks, James |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Open forum infectious diseases |d 2014 |g 8(2021), 9 vom: 17. Sept., Seite ofab420 |w (DE-627)NLM243576811 |x 2328-8957 |7 nnns |
| 773 | 1 | 8 | |g volume:8 |g year:2021 |g number:9 |g day:17 |g month:09 |g pages:ofab420 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1093/ofid/ofab420 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 8 |j 2021 |e 9 |b 17 |c 09 |h ofab420 | ||